Classification
Compound class	Antibody
Approved drug?	Yes (FDA (1998), EMA (1999))

International Nonproprietary Names
INN number	INN
7602	infliximab

Synonyms

cA2 | Inflectra® | Remicade® | Remsima® | SB2 | TA-650

Comments

Infliximab is an anti-tumour necrosis factor (TNF)α, mouse-human chimeric monoclonal antibody. It binds both soluble and transmembrane forms of TNFα but not lymphotoxin α (TNFβ). Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis reveals this to be antibody cA2 in patent US5656272 [4]. Biosimilars: Name Trade name Company Clinical Phase Indications References infliximab-dyyb; CT-P13 Remsima; Inflectra Celltrion Approved (2013 EMA, 2016 FDA) As per reference agent [1-2,7] infliximab-abda; SB2 Flixabi; Renflexis Biogen Approved (2016 EMA, 2017 FDA) As per reference agent   infliximab-qbtx; PF-06438179 Ixifi Pfiizer Approved (2017 FDA) As per reference agent [3] NI-071   Nichi-Iko Pharmaceutical Approved (2017 Japan); Phase 3 US (NCT02990806) As per reference agent   BCD-055   Biocad Ph 3 (NCT02762838) Rheumatoid arthritis   Infliximab-EPIRUS; BOW015   Epirus Biopharmaceuticals Ph 3 (NCT02683564) Rheumatoid arthritis   ABP 710   Amgen Ph 3 (NCT02937701) Rheumatoid arthritis

Database Links
Specialist databases
IMGT/mAb-DB	156
Other databases
GtoPdb PubChem SID	178101701
PubChem SID	178101701
Search PubMed clinical trials	infliximab
Search PubMed titles	infliximab
Search PubMed titles/abstracts	infliximab
Wikipedia	Infliximab